• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Enanta Pharmaceuticals Inc. filed SEC Form 8-K: Regulation FD Disclosure

    12/9/24 8:29:32 AM ET
    $ENTA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ENTA alert in real time by email
    8-K
    ENANTA PHARMACEUTICALS INC false 0001177648 0001177648 2024-12-09 2024-12-09

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

     

    FORM 8-K

     

     

    CURRENT REPORT

    Pursuant to Section 13 or 15(d)

    of the Securities Exchange Act of 1934

    Date of Report (Date of earliest event reported): December 9, 2024

     

     

    ENANTA PHARMACEUTICALS, INC.

    (Exact name of Registrant as Specified in Its Charter)

     

     

     

    Delaware   001-35839   04-3205099
    (State or Other Jurisdiction
    of Incorporation)
     

    (Commission

    File Number)

      (IRS Employer
    Identification No.)

    4 Kingsbury Avenue

    Watertown, Massachusetts

        02472
    (Address of Principal Executive Offices)     (Zip Code)

    Registrant’s Telephone Number, Including Area Code: (617) 607-0800

    Not Applicable

    (Former Name or Former Address, if Changed Since Last Report)

     

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

     

    ☐

    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

     

    ☐

    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

     

    ☐

    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

     

    ☐

    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class

     

    Trading

    Symbol(s)

     

    Name of each exchange

    on which registered

    Common Stock, par value $0.01 per share   ENTA   Nasdaq Global Select Market

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

    Emerging growth company ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     

     


    Item 7.01

    Regulation FD Disclosure.

    On December 9, 2024, Enanta Pharmaceuticals, Inc. (“Enanta”) issued a press release announcing positive topline data from its Phase 2 pediatric study of zelicapavir (formerly EDP-938) for the treatment of respiratory syncytial virus (“RSV”). A copy of the press release is furnished as Exhibit 99.1 hereto and is incorporated herein by this reference. In connection with such data release, the Company compiled a presentation entitled “Phase 2 Study of Zelicapavir in Children: RSVPEDs Topline Results” (the “Presentation”) that includes the topline data from its Phase 2 pediatric study of zelicapavir for the treatment of RSV referenced above. A copy of the Presentation is furnished as Exhibit 99.2.

    The information in Item 7.01 of this Current Report on Form 8-K, including Exhibits 99.1 and 99.2 attached hereto, is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities and Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in any such filing.

     

    Item 8.01

    Other Events.

    As noted in Item 7.01 above, Enanta announced positive topline data from its Phase 2 pediatric study of zelicapavir for the treatment of RSV on December 9, 2024.

    This Phase 2 study was a randomized, double-blind, dose ranging, placebo-controlled study in hospitalized and non-hospitalized pediatric patients with RSV aged 28 days to 36 months. The primary objective of Part 1 of the study was to evaluate the safety and pharmacokinetics of zelicapavir and to determine the optimal dosing for Part 2 of the study. The primary objective of Part 2 of the study was to evaluate the antiviral activity of zelicapavir, with assessment of symptom severity as an exploratory objective. Because exposure was similar across all cohorts and doses, and all patients received a therapeutic dose, primary efficacy analyses were able to be performed across all dosed patients from Parts 1 and 2.

    A total of 96 patients received zelicapavir (n=70) or placebo (n=26). Part 1 evaluated multiple doses and patients were treated with zelicapavir (n=36) or placebo (n=16) once-daily (QD) for 5 days. In Part 2, patients received the selected dose of zelicapavir (n=34) or placebo (n=10) QD for 5 days. Demographics and baseline characteristics were balanced across treatment groups, with the majority of patients being hospitalized at enrollment, and a mean duration of RSV symptoms prior to randomization of 4 days.

    Zelicapavir demonstrated a favorable safety profile over the initial 5-day dosing period and through 23 days of follow-up. Adverse events (AEs) were similar between zelicapavir and placebo, and the most common AEs (occurring in more than one patient) were diarrhea, rash, otitis media acute, eczema, thrombocytosis and nasopharyngitis with one serious adverse event (SAE) in the zelicapavir group, which was a case of community-acquired pneumonia reported 22 days after the patient began the trial and was deemed not treatment related, and two SAEs in the placebo group. There were no AEs leading to treatment discontinuation or study withdrawal. Furthermore, zelicapavir achieved target drug exposure levels across all age groups and dosing cohorts. Exposure was similar across cohorts and doses, and all patients received a therapeutic dose. A dose of 5 mg/kg was selected for age ≥ 28 days to <12 months, and a dose of 7.5 mg/kg was selected for age ≥12 months to ≤36 months.

    An antiviral effect was observed for the primary and secondary virology endpoints in the overall pooled efficacy population, with the viral load decline peaking at 0.7 log on Day 9 compared to placebo. The primary endpoint for Part 2 of the study showed a more pronounced effect, with a viral load decline of 1.0 log at Day 3 and 1.4 log at Day 5 compared to placebo. Additionally, a rapid and robust antiviral effect was observed in the prespecified subset of patients who were randomized within 3 days of symptom onset, which represents about 40% of patients in the study (n=38/96). In these patients, a viral load decline of 0.9 log at Day 3 and 1.2 log at Day 5 was observed compared to


    placebo. Furthermore, zelicapavir treatment resulted in a greater proportion of patients having undetectable viral load at Days 5 and 9 compared to placebo and improvements in AUC of change from baseline for viral load at all timepoints. Qualitative improvement in time to undetectable viral load was observed at early timepoints, although median time to undetectable viral load was similar between groups. Overall, virology results were similar regardless of age or whether patients were enrolled from a hospitalized or outpatient setting.

    As there are no validated symptom tools approved by regulatory agencies for pediatric RSV, multiple methods were used to assess symptoms. ReSViNET (REspiratory Syncytial VIrus NETwork), a publicly available pediatric tool with caregiver assessments, was used as an exploratory endpoint in all patients. This tool was originally designed primarily for prophylaxis studies to assess disease severity at a single timepoint. There was no difference in symptoms between zelicapavir and placebo using ReSViNET. RESOLVE-P (RESpiratory ObservabLE Reported Outcome-Pediatric), a proprietary tool being developed by Enanta in alignment with regulatory agency input, was specifically designed to assess the severity of pediatric RSV infection change over time based on observations by the child’s caregiver. As this tool was finalized and introduced late in the study, data are only available from a small number of patients (n=15). In this dataset, a trend toward greater symptom reduction in patients treated with zelicapavir was observed.

    Forward Looking Statements

    This Current Report on Form 8-K includes forward-looking statements, including with respect to the prospects for further development and advancement of zelicapavir for the treatment of RSV. Statements that are not historical facts are based on management’s current expectations, estimates, forecasts and projections about Enanta’s business and the industry in which it operates and management’s beliefs and assumptions. The statements contained in this report are not guarantees of future performance and involve certain risks, uncertainties and assumptions, which are difficult to predict. Therefore, actual outcomes and results may differ materially from what is expressed in such forward-looking statements. Important factors and risks that may affect actual results include: the development risks of early stage discovery efforts in the disease areas in Enanta’s research and development pipeline, such as RSV; the impact of development, regulatory and marketing efforts of others with respect to vaccines and competitive treatments for RSV; Enanta’s limited clinical development experience; Enanta’s need to attract and retain senior management and research and development personnel; Enanta’s need to obtain and maintain patent protection for its product candidates and avoid potential infringement of the intellectual property rights of others; and other risk factors described or referred to in “Risk Factors” in Enanta’s most recent Annual Report on Form 10-K for the fiscal year ended September 30, 2024 and other periodic reports filed more recently with the Securities and Exchange Commission. Enanta cautions investors not to place undue reliance on the forward-looking statements contained in this report. All forward-looking statements contained in this report speak only as of the date on which they were made and are based on management’s assumptions and estimates as of such date. Enanta undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law.

     

    Item 9.01

    Financial Statements and Exhibits.

    (d) Exhibits

     

    Exhibit

    Number

      

    Exhibit Description

    99.1    Press release dated December 9, 2024
    99.2    Slide presentation entitled “Phase 2 Study of Zelicapavir in Children: RSVPEDs Topline Results”
    104    Cover Page Interactive Data File (embedded within the Inline XBRL document)


    SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

    Date: December 9, 2024   ENANTA PHARMACEUTICALS, INC.
        By:  

    /s/ Paul J. Mellett

          Paul J. Mellett
          Chief Financial and Administrative Officer
    Get the next $ENTA alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $ENTA

    DatePrice TargetRatingAnalyst
    8/9/2023$14.00Neutral → Underweight
    JP Morgan
    8/8/2023$49.00 → $18.00Buy → Hold
    Jefferies
    12/9/2022$56.00Buy
    H.C. Wainwright
    7/6/2022$62.00In-line → Outperform
    Evercore ISI
    6/1/2022$39.00Underperform → In-line
    Evercore ISI
    2/9/2022$80.00 → $68.00Market Perform
    SVB Leerink
    1/13/2022$85.00 → $80.00Market Perform
    SVB Leerink
    11/24/2021$55.00 → $73.00Perform
    Oppenheimer
    More analyst ratings

    $ENTA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • President and CEO Luly Jay R. bought $256,050 worth of shares (45,000 units at $5.69), increasing direct ownership by 6% to 846,638 units (SEC Form 4)

      4 - ENANTA PHARMACEUTICALS INC (0001177648) (Issuer)

      2/12/25 8:09:35 PM ET
      $ENTA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ENTA
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Enanta Pharmaceuticals' Partner AbbVie Receives U.S. FDA Approval of an Expanded Indication for MAVYRET® (glecaprevir/pibrentasvir) as the First and Only Treatment for People with Acute Hepatitis C Virus

      MAVYRET® (glecaprevir/pibrentasvir) is Now the Only Direct Acting Antiviral Therapy Approved to Treat Patients with Acute Hepatitis C Virus (HCV) in Eight Weeks with a 96% Cure Rate1*† FDA Approval Now Allows Providers to Treat HCV Patients Immediately at Time of Diagnosis If Left Untreated, Patients with Acute HCV Could Progress to Chronic Disease, Including Cirrhosis or Liver Cancer2 Glecaprevir, One of the Two Direct-Acting Antivirals in MAVYRET®, was Discovered by Enanta and Developed and Commercialized by AbbVie Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunologica

      6/11/25 12:34:00 PM ET
      $ENTA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Enanta Pharmaceuticals to Present at the Jefferies Global Healthcare Conference

      Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological diseases, today announced that Jay R. Luly, Ph.D., President and Chief Executive Officer, will participate in a fireside chat at the Jefferies Global Healthcare Conference on Thursday, June 5, 2025 at 8:10 a.m. ET in New York, NY. A live webcast of the event will be accessible by visiting the "Events and Presentations" section on the "Investors" page of Enanta's website at www.enanta.com. A replay of the webcast will be available following the presentation and will be archived for at least 30 days. About Enanta Pharmaceuticals

      5/27/25 7:00:00 AM ET
      $ENTA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Enanta Pharmaceuticals Announces Data from its Phase 2 Study of Zelicapavir in Children with Respiratory Syncytial Virus to be Presented at the 43rd Annual ESPID Meeting

      Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological diseases, today announced that data from the Company's Phase 2 study of zelicapavir in young children infected with respiratory syncytial virus (RSV) will be available as an E-Poster at the 43rd Annual Meeting of the European Society for Paediatric Infectious Diseases (ESPID) 2025, being held May 26-30, 2025 at the Bucharest International Conference Centre in Bucharest, Romania and online. The E-Poster will highlight results from a Phase 2 study of zelicapavir, an oral, non-nucleoside small-molecule RSV-replication-inhibitor (N

      5/22/25 7:00:00 AM ET
      $ENTA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ENTA
    SEC Filings

    See more
    • SEC Form S-8 filed by Enanta Pharmaceuticals Inc.

      S-8 - ENANTA PHARMACEUTICALS INC (0001177648) (Filer)

      5/14/25 4:41:15 PM ET
      $ENTA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by Enanta Pharmaceuticals Inc.

      10-Q - ENANTA PHARMACEUTICALS INC (0001177648) (Filer)

      5/14/25 4:00:25 PM ET
      $ENTA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Enanta Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - ENANTA PHARMACEUTICALS INC (0001177648) (Filer)

      5/12/25 4:05:15 PM ET
      $ENTA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ENTA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director Vance Terry

      4 - ENANTA PHARMACEUTICALS INC (0001177648) (Issuer)

      3/14/25 5:44:01 PM ET
      $ENTA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Russell Lesley

      4 - ENANTA PHARMACEUTICALS INC (0001177648) (Issuer)

      3/14/25 5:43:30 PM ET
      $ENTA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Peterson Kristine

      4 - ENANTA PHARMACEUTICALS INC (0001177648) (Issuer)

      3/14/25 5:43:00 PM ET
      $ENTA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ENTA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Enanta Pharmaceuticals downgraded by JP Morgan with a new price target

      JP Morgan downgraded Enanta Pharmaceuticals from Neutral to Underweight and set a new price target of $14.00

      8/9/23 7:32:28 AM ET
      $ENTA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Enanta Pharmaceuticals downgraded by Jefferies with a new price target

      Jefferies downgraded Enanta Pharmaceuticals from Buy to Hold and set a new price target of $18.00 from $49.00 previously

      8/8/23 6:35:35 AM ET
      $ENTA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • H.C. Wainwright initiated coverage on Enanta Pharmaceuticals with a new price target

      H.C. Wainwright initiated coverage of Enanta Pharmaceuticals with a rating of Buy and set a new price target of $56.00

      12/9/22 7:40:58 AM ET
      $ENTA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ENTA
    Financials

    Live finance-specific insights

    See more
    • Enanta Pharmaceuticals Reports Financial Results for its Fiscal Second Quarter Ended March 31, 2025

      Met Target Enrollment for RSVHR, a Phase 2 Study of Zelicapavir in High-Risk Adults Infected with Respiratory Syncytial Virus (RSV); On Track to Report Topline Data in Late 3Q 2025 STAT6 Program Progressing with Plans to Select a Development Candidate in 2H 2025 IND Enabling Studies of KIT Inhibitor EPS-1421 Ongoing Cash and Marketable Securities Totaling $193.4 Million at March 31, 2025, Further Strengthened by a $33.8 Million Federal Income Tax Refund Received in April 2025 Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological diseases, today reported financial results f

      5/12/25 4:01:00 PM ET
      $ENTA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Enanta Pharmaceuticals Reports Financial Results for its Fiscal First Quarter Ended December 31, 2024

      On Track to Report Topline Results for RSVHR, a Phase 2 Study of Zelicapavir in High-Risk Adults Infected with Respiratory Syncytial Virus (RSV), in 3Q 2025 Advancing Immunology Portfolio with Ongoing IND Enabling Studies of KIT Inhibitor EPS-1421 On Track to Announce STAT6 Development Candidate in 2H 2025 Operations Supported by Cash and Marketable Securities Totaling $216.7 Million at December 31, 2024, as well as Continuing Retained Royalties Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for virology and immunology indications, today reported financial results for its fiscal first quarter ended D

      2/10/25 4:01:00 PM ET
      $ENTA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Enanta Pharmaceuticals Announces Positive Topline Results from First-in-Pediatrics Phase 2 Study Evaluating Zelicapavir for the Treatment of Respiratory Syncytial Virus (RSV)

      Observed an antiviral effect for the primary and secondary virology endpoints in the overall population, with a viral load decline of 1.4 log at the end of treatment in Part 2 Demonstrated a viral load decline of 1.2 log compared to placebo at the end of treatment in prespecified analysis of patients randomized within 3 days of symptom onset Zelicapavir was well-tolerated with a favorable safety profile Conference call and webcast to discuss data at 8:30 a.m. ET today Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for virology and immunology indications, today announced positive topline results from

      12/9/24 6:30:00 AM ET
      $ENTA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ENTA
    Leadership Updates

    Live Leadership Updates

    See more
    • Enanta Pharmaceuticals Announces the Appointment of Matthew P. Kowalsky as Chief Legal Officer

      Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for virology and immunology indications, today announced the appointment of Matthew P. Kowalsky, J.D., as Chief Legal Officer. In this role, he will lead all legal and compliance activities for Enanta, as well as provide strategic guidance and corporate governance oversight. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240430622885/en/Matthew P. Kowalsky, Chief Legal Officer, Enanta Pharmaceuticals, Inc. (Photo: Business Wire) "I'm pleased to welcome Matt to Enanta. The breadth of his legal expertise ac

      4/30/24 7:00:00 AM ET
      $ENTA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Enanta Pharmaceuticals Appoints Scott T. Rottinghaus, M.D., as Senior Vice President and Chief Medical Officer

      Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating novel, small molecule drugs for viral infections and liver diseases, today announced the appointment of Scott T. Rottinghaus, M.D., as Senior Vice President and Chief Medical Officer, effective today, August 8, 2022. With over 20 years of experience in drug development across a broad range of therapeutic areas, Dr. Rottinghaus will lead the development, regulatory, clinical and medical functions in support of Enanta's pipeline. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220808005491/en/Scott T. Rottinghaus, M.D., Senior Vi

      8/8/22 4:00:00 PM ET
      $ENTA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Enanta Pharmaceuticals Announces the Appointment of Brendan Luu as Senior Vice President, Business Development

      WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA), a clinical stage biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced the appointment of Brendan Luu as Senior Vice President, Business Development and member of the company’s senior management team. Mr. Luu brings more than 20 years of diversified business development and sales and marketing experience in the pharmaceutical and technology fields to Enanta, spanning a broad range of therapeutic areas, asset stages and deal structures. “It is an ideal time to welcome Brendan to the Enanta team, particularly as we prepare for a catalys

      1/26/21 7:00:00 AM ET
      $ENTA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ENTA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Enanta Pharmaceuticals Inc.

      SC 13G/A - ENANTA PHARMACEUTICALS INC (0001177648) (Subject)

      11/14/24 4:03:02 PM ET
      $ENTA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Enanta Pharmaceuticals Inc.

      SC 13G/A - ENANTA PHARMACEUTICALS INC (0001177648) (Subject)

      10/17/24 4:31:00 PM ET
      $ENTA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Enanta Pharmaceuticals Inc. (Amendment)

      SC 13G/A - ENANTA PHARMACEUTICALS INC (0001177648) (Subject)

      2/14/24 2:26:49 PM ET
      $ENTA
      Biotechnology: Pharmaceutical Preparations
      Health Care